Business
Innocan Pharma Announces Offering of an Additional Debenture to Tamar Innovest
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it intends to complete an offering of a debenture of the Company (the "Debenture") to its largest shareholder, Tamar Innovest Ltd. ("Tamar Innovest") for gross proceeds of US $200,000 (the "Offering"). This follows the completion of the offering to Tamar Innovest of a debenture in the principal amount of US $450,000 (the "Prior Debenture") to Tamar Innovest on March 11, 2026.
About this update from Innocan Pharma Corporation
[{"type":"text","content":"HERZLIYA, Israel and CALGARY, AB, March 31, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it intends to complete an offering of a debenture of the Company (the "Debenture") to its largest shareholder, Tamar Innovest Ltd. ("Tamar Innovest") for gross proceeds of US $200,000 (the "Offering"). This follows the completion of the offering to Tamar Innovest of a debenture in the principal amount of US $450,000 (the "Prior Debenture") to Tamar Innovest on March 11, 2026.","length":628,"tagName":"p"},{"type":"image","alt":"Innocan Pharma Corporation logo","displaySize":"","headline":null,"caption":"Innocan Pharma Corporation logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":283,"url":"https://media.zenfs.com/en/cnwgroup.com/7706f970d25ba77672f989a1db7cd166"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/mwWxNodzAcIg.nuNsywIdg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ5OQ--/https://media.zenfs.com/en/cnwgroup.com/7706f970d25ba77672f989a1db7cd166","width":400,"height":283}}},{"type":"text","content":"The Debenture will be on the same terms as the Prior Debenture and will bear interest at the rate of 10% per annum and will mature at the earlier of: (i) 12 months from the date of issuance; and (ii) the completion of the Company's previously announced proposed public offering in the United States pursuant to its registration statement on F-1 filed with the U.S. Securities and Exchange Commission, as amended. The Debenture will be secured by the general security agreement already entered into by the parties on March 7, 2025 and related security interest filed under the laws of the Province of Alberta.","length":612,"tagName":"p"},{"type":"text","content":"The Offering is expected to close on or around April 1, 2026. Innocan intends to use the proceeds of the Offering for working capital and general corporate purposes.","length":165,"tagName":"p"},{"type":"text","content":"Tamar Innovest currently beneficially owns and controls 765,020 Common Shares representing 17.00 % of the current issued and outstanding Common Shares and is an insider of the Company. Tamar Innovest is managed by Ralph Bossino, a director of the Company. As such, Tamar Inn...